KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Operating Expenses (2017 - 2025)

Teva Pharmaceutical Industries (TEVA) has disclosed Operating Expenses for 9 consecutive years, with $634.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Operating Expenses rose 15.48% year-over-year to $634.0 million, compared with a TTM value of $1.8 billion through Dec 2025, down 16.58%, and an annual FY2025 reading of $2.3 billion, up 6.53% over the prior year.
  • Operating Expenses was $634.0 million for Q4 2025 at Teva Pharmaceutical Industries, up from $317.0 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $1.0 billion in Q4 2022 and bottomed at $306.0 million in Q2 2025.
  • Average Operating Expenses over 5 years is $534.8 million, with a median of $525.5 million recorded in 2022.
  • The sharpest move saw Operating Expenses surged 99.23% in 2022, then plummeted 50.1% in 2023.
  • Year by year, Operating Expenses stood at $520.0 million in 2021, then soared by 99.23% to $1.0 billion in 2022, then plummeted by 50.1% to $517.0 million in 2023, then rose by 6.19% to $549.0 million in 2024, then increased by 15.48% to $634.0 million in 2025.
  • Business Quant data shows Operating Expenses for TEVA at $634.0 million in Q4 2025, $317.0 million in Q3 2025, and $306.0 million in Q2 2025.